[ad_1]
BioMarin Pharmaceutical Inc.’s (NASDAQ:) Chief Accounting Officer, Erin Burkhart, has sold a portion of her company stock, according to a recent filing with the Securities and Exchange Commission. The transaction, which took place on April 10, involved the sale of 2,286 shares at a price of $90.0 per share, totaling approximately $205,740.
The sale was conducted under a prearranged 10b5-1 trading plan, which allows company insiders to sell shares at predetermined times to avoid accusations of insider trading. This particular plan was put in place on November 29, 2023.
Following the sale, Burkhart still retains 16,156 shares of BioMarin stock, indicating a continued investment in the company’s future. BioMarin, a pharmaceutical company specializing in therapies for rare genetic diseases, has not made any additional comments regarding the transaction.
Investors often monitor insider transactions as they can provide insights into an executive’s confidence in the company’s prospects. However, transactions under 10b5-1 plans are typically scheduled in advance and may not always reflect the insider’s discretionary trading based on current market conditions or company performance.
BioMarin’s stock continues to be watched by investors interested in the biotech and pharmaceutical sectors, particularly those focused on innovative treatments for rare diseases.
InvestingPro Insights
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has been a point of interest for investors looking at the biotech and pharmaceutical sectors. Recent data and analysis from InvestingPro provide further insights into the company’s financial health and stock performance.
InvestingPro Tips suggest that BioMarin is expected to see net income growth this year, which could be a positive signal for investors. However, it’s important to note that 8 analysts have revised their earnings downwards for the upcoming period, indicating potential concerns about the company’s near-term financial prospects.
In terms of valuation, BioMarin is trading at a high earnings multiple, with a P/E ratio of 102.63, which is adjusted to 85.43 for the last twelve months as of Q4 2023. This high P/E ratio relative to near-term earnings growth could suggest that the stock is priced optimistically in terms of its earnings potential. Despite this, the company operates with a moderate level of debt and its liquid assets exceed short-term obligations, which may provide some financial stability.
InvestingPro Data highlights include a market capitalization of $17.38 billion USD and a revenue growth of 15.42% over the last twelve months as of Q4 2023. The company’s gross profit margin stands at 47.85%, reflecting its ability to maintain profitability on its sales.
For those looking to delve deeper into BioMarin’s financials and stock performance, InvestingPro offers additional tips on its platform. To explore these insights and more, investors can visit https://www.investing.com/pro/BMRN and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 13 additional InvestingPro Tips available that could help investors make more informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
[ad_2]
Source link
